Related News
Stroke patient receives stem cell therapy
Source: Agencies |
November 17, 2010, Wednesday
|
Print Edition
Print Edition
Doctors in Scotland working with British biotech company ReNeuron have treated the first patient in a pioneering clinical trial to test whether stem cell therapy can help patients disabled by stroke.
The trial is the first in the world to use neural stem cell therapy in stroke patients, its organizers said yesterday, and external experts said it was grounds for "cautious optimism."
Keith Muir of the University of Glasgow's Institute of Neuroscience and Psychology, the principal investigator, said the first patient had undergone a successful surgical procedure and been discharged from hospital.
The procedure involves injecting ReNeuron's neural stem cells into patients' brains in the hope they will repair areas damaged by stroke, thereby improving both mental and physical function.
Unlike US company Geron's clinical trial in patients with spinal cord injuries, which started last month, the Scottish study uses stem cells derived from human fetuses rather than embryos.
Fetal stem cells do not have the same flexibility to turn into different tissue types as embryonic ones.
Scientists commenting on news of the trial said it was important to guard against raising expectations of miracle cures for thousands of patients in the near future.
"The current trial will require extensive tests for efficacy and safety," said Darren Griffin, a professor of genetics at Britain's Kent University, who is not involved in the study. "Nevertheless there is room for cautious optimism."
In total, 12 patients will get ReNeuron's ReN001 cell therapy between six and 24 months after having an ischaemic stroke - caused by a blockage of blood flow in the brain - and their progress will be followed for two years in the trial.
If the first study is successful, researchers plan to pursue accelerated clinical development in later-stage clinical trials, focusing initially on more severely disabled stroke patients.
Stem-cell technology is viewed as a highly promising new area of medical science, but it has proved controversial, in part because some cell lines are derived from embryos or fetuses. Other research teams are also working with adult stem cells.
The trial is the first in the world to use neural stem cell therapy in stroke patients, its organizers said yesterday, and external experts said it was grounds for "cautious optimism."
Keith Muir of the University of Glasgow's Institute of Neuroscience and Psychology, the principal investigator, said the first patient had undergone a successful surgical procedure and been discharged from hospital.
The procedure involves injecting ReNeuron's neural stem cells into patients' brains in the hope they will repair areas damaged by stroke, thereby improving both mental and physical function.
Unlike US company Geron's clinical trial in patients with spinal cord injuries, which started last month, the Scottish study uses stem cells derived from human fetuses rather than embryos.
Fetal stem cells do not have the same flexibility to turn into different tissue types as embryonic ones.
Scientists commenting on news of the trial said it was important to guard against raising expectations of miracle cures for thousands of patients in the near future.
"The current trial will require extensive tests for efficacy and safety," said Darren Griffin, a professor of genetics at Britain's Kent University, who is not involved in the study. "Nevertheless there is room for cautious optimism."
In total, 12 patients will get ReNeuron's ReN001 cell therapy between six and 24 months after having an ischaemic stroke - caused by a blockage of blood flow in the brain - and their progress will be followed for two years in the trial.
If the first study is successful, researchers plan to pursue accelerated clinical development in later-stage clinical trials, focusing initially on more severely disabled stroke patients.
Stem-cell technology is viewed as a highly promising new area of medical science, but it has proved controversial, in part because some cell lines are derived from embryos or fetuses. Other research teams are also working with adult stem cells.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
